| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Michelle McMurry-Heath is Director at BVS, with reported holdings spanning 2 companies. Michelle McMurry-Heath's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Our model assigns Michelle McMurry-Heath a middling insider score of 52/100, based on 5 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +0.5%.
Michelle McMurry-Heath's largest disclosed position is in RVTY as Director, worth about $1.1M. The RVTY filings lean toward selling, a net 3,170 shares.
Michelle McMurry-Heath has 19 Form 4 filings on record from January 2022 to June 2026, across 2 companies: Director at Bioventus (BVS), 2022–2026; Director at Revvity (RVTY), 2022–2026.
The 28 reported transactions were 10 stock awards, 7 option exercises, 6 option or other derivative awards and 5 open-market sales.
Counted by filing, the open-market trades come to no purchases and 5 sales worth about $586K.
The largest open-market sale was 1,970 shares of RVTY at an average $119.49 on February 6, 2025, about $235K. Twelve months later RVTY was down 15%.
None of the 5 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | BVS Bioventus Inc. | Director | Sell | 12,000 | $8.79 | $105,439.20 | -21.1% | +3.4% | - | |
| Feb 23, 2026 | RVTY Revvity, Inc. | Director | Sell | 600 | $97.26 | $58,356.00 | -12.4% | -0.3% | - | |
| Nov 7, 2025 | BVS Bioventus Inc. | Director | Sell | 17,701 | $7.42 | $131,254.69 | -23.7% | +10.2% | - | |
| May 29, 2025 | RVTY Revvity, Inc. | Director | Sell | 600 | $92.17 | $55,299.00 | -11.0% | -3.6% | +13.8% | |
| Feb 6, 2025 | RVTY Revvity, Inc. | Director | Sell | 1,970 | $119.49 | $235,395.30 | -39.5% | -23.1% | -14.7% |